KR840004101A - 1,2,4-트리아진 및 피라진 유도체의 제조방법 - Google Patents

1,2,4-트리아진 및 피라진 유도체의 제조방법 Download PDF

Info

Publication number
KR840004101A
KR840004101A KR1019830000833A KR830000833A KR840004101A KR 840004101 A KR840004101 A KR 840004101A KR 1019830000833 A KR1019830000833 A KR 1019830000833A KR 830000833 A KR830000833 A KR 830000833A KR 840004101 A KR840004101 A KR 840004101A
Authority
KR
South Korea
Prior art keywords
formula
alkyl
compound
phenyl
ocoa
Prior art date
Application number
KR1019830000833A
Other languages
English (en)
Other versions
KR860000847B1 (ko
Inventor
타이와이옹 다비드 (외 1)
Original Assignee
아더 알. 웨일
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아더 알. 웨일, 일라이 릴리 앤드 캄파니 filed Critical 아더 알. 웨일
Publication of KR840004101A publication Critical patent/KR840004101A/ko
Application granted granted Critical
Publication of KR860000847B1 publication Critical patent/KR860000847B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/16—Halogen atoms; Nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Inks, Pencil-Leads, Or Crayons (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

내용 없음

Description

1,2,4-트리아진 및 피라진 유도체의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 다음 일반식( II )의 전구체 화합물을 다음 일반식( III )의 아민과 반응시키고, 필요한경우 W가 하이드록실인 일반식( I )의 화합물을 알킬화 또는 에스테르화시키거나, W가 일반식 -OCOA으 그룹(여기서 A는아미노 또는 모노-또는 디-C1C3알킬아미노그룹임)인 일반식( I )의 화합물을 제조하기 위해서는, W가 일반식페닐인 일반식( I )의 화합물을 암모니아 또는 일반식 HNR17R18의 아민과 반응시킴을특징으로 하여, 다음 일반식( I )의 화합물 및 이의 약학적으로 무독한 염을 제조하는 방법.
    페닐 (Ⅳ)
    상기 일반식에서, R1및 R2는 독립적으로 C1-C3알킬 또는 클로로이고, X는 CH 또는 N이고, Q는 산소 또는 -(CH2)n-이고, n은 0, 1 또는 2이고, W는 수소,C1-C3알킬,C1-C3알콕시, 하이드록시, 하이드록시메틸,-OCHO,-OCOA,-OSO2A 또는 -COB중에서 선택된 1가의 라디칼이거나, =0, =NOH또는중에서 선택된 2가의 라디칼이고, A는 C1-C4알킬, 페닐,펜옥시, 아미노,C1-C3알킬-치환된 페닐 또는 모노-또는 디-C1-C3알킬아미노이고-B는 C1-C3알콕시, 아미노 또느 모노-또는 디-C1-C3알킬아미노이고, R3는 친핵 치환될수 있는 이탈기이고 R17은 C1-C3알킬이고 R18은 수소 또는 C1-C3알킬이다.
  2. 제1항에 있어서, R1및 R2가 4-클로로인 방법.
  3. 제1항에 있어서, R1및 R2가 4-메틸인 방법.
  4. 제1항 내지 3항중 어느 하나에 있어서, Q가 -(CH2)n인 방법.
  5. 제1항 내지 3항중 어느 하나에 있어서, X가 N인 방법.
  6. 제1항 내지 3항중 어느 하나에 있어서, W가 하이드록시인 방법.
  7. 제1항 내지 5항중 어느 하나에 있어서, W가 -OCOA인 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019830000833A 1982-03-05 1983-03-02 1,2,4-트리아진 및 피라진 유도체의 제조방법 KR860000847B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US354,982 1982-03-05
US06/354,982 US4513135A (en) 1982-03-05 1982-03-05 Diaryl-pyrazine derivatives affecting GABA binding

Publications (2)

Publication Number Publication Date
KR840004101A true KR840004101A (ko) 1984-10-06
KR860000847B1 KR860000847B1 (ko) 1986-07-09

Family

ID=23395746

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019830000833A KR860000847B1 (ko) 1982-03-05 1983-03-02 1,2,4-트리아진 및 피라진 유도체의 제조방법

Country Status (22)

Country Link
US (2) US4513135A (ko)
EP (1) EP0088593B1 (ko)
JP (1) JPS58162582A (ko)
KR (1) KR860000847B1 (ko)
AT (1) ATE27457T1 (ko)
AU (1) AU547581B2 (ko)
CA (1) CA1195327A (ko)
DD (1) DD207716A5 (ko)
DE (1) DE3371786D1 (ko)
DK (1) DK97283A (ko)
ES (2) ES520340A0 (ko)
FI (1) FI830708L (ko)
GB (1) GB2116179B (ko)
GR (1) GR78459B (ko)
HU (1) HU191368B (ko)
IL (1) IL68002A (ko)
NZ (1) NZ203428A (ko)
PH (1) PH22535A (ko)
PL (1) PL240871A1 (ko)
PT (1) PT76312B (ko)
RO (1) RO86320B (ko)
ZA (1) ZA831387B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100490893B1 (ko) * 2002-10-11 2005-05-23 (주) 비엔씨바이오팜 2-메톡시-1,3,5-트리아진 유도체, 그 제조방법 및 이를 포함하는 항바이러스용 약학적 조성물

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2567518B1 (fr) * 1984-07-11 1987-11-13 Sanofi Sa Nouveaux composes a noyau heterocyclique azote, leur preparation et les medicaments qui en contiennent
WO1992002513A1 (en) * 1990-08-06 1992-02-20 Fujisawa Pharmaceutical Co., Ltd. Heterocyclic compounds
GB9420010D0 (en) * 1994-10-01 1994-11-16 Marck Sharp & Dohme Limited Nucleic acids
WO1998003167A1 (en) 1996-07-24 1998-01-29 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
TWI316055B (ko) * 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
US20070003394A1 (en) * 2005-02-01 2007-01-04 Carey Paul G Anti-cross threading fastener
TW200716594A (en) * 2005-04-18 2007-05-01 Neurogen Corp Substituted heteroaryl CB1 antagonists
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
DK2531492T3 (en) 2010-02-05 2016-07-04 Heptares Therapeutics Ltd 1,2,4-triazin-4-amine derivatives
GB201106829D0 (en) 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
TW201321353A (zh) * 2011-10-08 2013-06-01 Novartis Ag 胺基甲酸酯／尿素衍生物
TN2019000010A1 (en) 2016-07-12 2020-07-15 Revolution Medicines Inc 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
JP6918828B2 (ja) * 2016-11-30 2021-08-11 田辺三菱製薬株式会社 トリアジン化合物の製造方法
WO2018136264A1 (en) 2017-01-23 2018-07-26 Revolution Medicines, Inc. Pyridine compounds as allosteric shp2 inhibitors
JP7240319B2 (ja) 2017-01-23 2023-03-15 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としての二環式化合物
BR112020004246A2 (pt) 2017-09-07 2020-09-01 Revolution Medicines, Inc. composições inibidoras de shp2 e métodos para o tratamento de câncer
AU2018347516A1 (en) 2017-10-12 2020-05-07 Revolution Medicines, Inc. Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors
KR20200099530A (ko) 2017-12-15 2020-08-24 레볼루션 메디슨즈, 인크. 알로스테릭 shp2 억제제로서의 다환식 화합물
AU2019262979B2 (en) 2018-05-01 2023-07-06 Revolution Medicines, Inc. C26-linked rapamycin analogs as mTOR inhibitors
CA3098692A1 (en) 2018-05-01 2019-11-07 Revolution Medicines, Inc. C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172889A (en) * 1965-03-09 Process for the separation of z-methyl-
US3294638A (en) * 1961-06-05 1966-12-27 Warner Lambert Pharmaceutical Method and compositions employing 2-alkyl-3-piperidinopyrazines
CH480795A (de) * 1967-03-01 1969-11-15 Sandoz Ag Mittel zur Beeinflussung des Pflanzenwachstums
US3948894A (en) * 1974-01-31 1976-04-06 Eli Lilly And Company 3-Amino-5,6-diaryl-1,2,4-triazines
US4013654A (en) * 1974-01-31 1977-03-22 Eli Lilly And Company 5,6-diaryl-1,2,4-triazines
US3989831A (en) * 1974-01-31 1976-11-02 Eli Lilly And Company Topically-active anti-inflammatory 3-chloro-5,6-diaryl-1,2,4-triazines
US3979516A (en) * 1974-01-31 1976-09-07 Eli Lilly And Company Anti-inflammatory 3-amino-5,6-diaryl-1,2,4-triazines
US4081542A (en) * 1975-04-21 1978-03-28 Merck & Co., Inc. Piperazinylpyrazines
GB1493998A (en) * 1975-06-03 1977-12-07 Beecham Group Ltd Propanolamine derivatives
US4008232A (en) * 1975-06-23 1977-02-15 Eli Lilly And Company 3-Amino-5,6-diaryl-1,2,4-triazines
US4082844A (en) * 1976-02-09 1978-04-04 Merck & Co., Inc. 6-chloro-2-(1-piperazinyl)pyrazine
US4190725A (en) * 1976-03-10 1980-02-26 Eli Lilly And Company 5,6-Diaryl-1,2,4-triazines
US4021553A (en) * 1976-03-10 1977-05-03 Eli Lilly And Company 5,6-Diaryl-1,2,4-triazines as topically-active anti-inflammatory agents
US4018923A (en) * 1976-03-10 1977-04-19 Eli Lilly And Company 5,6-Diaryl-1,2,4-triazines as topically-active anti-inflammatory agents
DE2810052A1 (de) * 1977-03-09 1978-09-14 Fabre Sa Pierre Aminoaryl-1,2,4-triazine, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
US4157392A (en) * 1977-05-17 1979-06-05 Diamond Shamrock Corporation Pharmacologically active substituted 1,2,4-triazines
CH633541A5 (en) * 1977-05-17 1982-12-15 Diamond Shamrock Corp Pharmacologically active substituted 1,2,4-triazines and medicaments containing these triazines
US4251527A (en) * 1977-05-17 1981-02-17 Diamond Shamrock Corporation Pharmacologically active substituted 1,2,4-triazines

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100490893B1 (ko) * 2002-10-11 2005-05-23 (주) 비엔씨바이오팜 2-메톡시-1,3,5-트리아진 유도체, 그 제조방법 및 이를 포함하는 항바이러스용 약학적 조성물

Also Published As

Publication number Publication date
FI830708A0 (fi) 1983-03-02
HU191368B (en) 1987-02-27
US4585861A (en) 1986-04-29
AU1202983A (en) 1983-09-08
GB2116179A (en) 1983-09-21
EP0088593A3 (en) 1984-05-23
PL240871A1 (en) 1984-06-18
EP0088593A2 (en) 1983-09-14
IL68002A0 (en) 1983-06-15
IL68002A (en) 1986-09-30
DE3371786D1 (en) 1987-07-02
CA1195327A (en) 1985-10-15
EP0088593B1 (en) 1987-05-27
GB8305846D0 (en) 1983-04-07
GR78459B (ko) 1984-09-27
DK97283A (da) 1983-09-06
FI830708L (fi) 1983-09-06
DK97283D0 (da) 1983-02-28
DD207716A5 (de) 1984-03-14
AU547581B2 (en) 1985-10-24
ES526297A0 (es) 1985-04-16
PT76312B (en) 1986-02-04
ZA831387B (en) 1984-10-31
RO86320B (ro) 1985-03-31
RO86320A (ro) 1985-03-15
GB2116179B (en) 1985-09-11
ES8404346A1 (es) 1984-04-16
JPS58162582A (ja) 1983-09-27
PT76312A (en) 1983-04-01
KR860000847B1 (ko) 1986-07-09
ES8504173A1 (es) 1985-04-16
PH22535A (en) 1988-10-17
US4513135A (en) 1985-04-23
ES520340A0 (es) 1984-04-16
ATE27457T1 (de) 1987-06-15
NZ203428A (en) 1986-09-10

Similar Documents

Publication Publication Date Title
KR840004101A (ko) 1,2,4-트리아진 및 피라진 유도체의 제조방법
MX9202849A (es) Analogos del agente antitumoral rebecamicina.
ES8201519A1 (es) Procedimiento para la preparacion de difenileteres
GB961037A (en) Pyrazolones and processes for their preparation
GB1446980A (en) A-aminooxy-carboxylic acid hydrazides
ES8105976A1 (es) Procedimiento para la preparacion de acilureas
KR840005107A (ko) 피리미디온 및 그의 산부가염의 제조방법
EP0083204A3 (en) 2-aminophenol derivatives and process for their preparation
KR850007588A (ko) β-나프틸알킬아민의 제조방법
ES8306161A1 (es) Un procedimiento para la preparacion de nuevos derivados de nitrosourea.
ES432006A1 (es) Procedimiento para preparar esteres de acidos o-fenil-tio- notiolfosforicos.
EP0014893A3 (en) 3-trifluorothiomethyl-2-(3-amino-2-subst.-propoxy)pyridines, their pharmaceutically acceptable salts and intermediates, their preparation and an antihypertensive composition containing them
ES451375A1 (es) Procedimiento para la preparacion de 2-4 diamino-5-bencil-pirimidinas.
ES502668A0 (es) Procedimiento para preparar una solucion hidrocarbonada de un compuesto de alquilsodio
KR840005721A (ko) 치환된 1,3,4-벤조트리아제핀의 제조방법
ES413742A1 (es) Un procedimiento para la preparacion de compuestos de acidol-alfa-hidrazino-betaf-fenilpropionico.
KR830007579A (ko) 피리미돈의 제조방법
KR830006244A (ko) 4-(아릴지방족)이속사졸의 제조방법
KR840002848A (ko) 유기인산염의 제조방법
KR860000285A (ko) 1,4-디하이드로피리딘 유도체의 제조방법
KR920004377A (ko) 피리딘카복실산 아미드 유도체 및 이를 함유하는 약제학적 조성물
KR840001544A (ko) 벤조페논유도체 제조방법
JPS51143657A (en) Process for preparing 2,4-dimethyl-3- carboxyanilido-furans
KR860000284A (ko) 디하이드로피리딘의 제조방법
KR830002798A (ko) 알킬-케토헥소 피라노사이드 유도체의 제조방법